BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 25678586)

  • 21. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
    Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
    Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
    Bryan BB; Schnitt SJ; Collins LC
    Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Hwang KT; Kim EK; Jung SH; Lee ES; Kim SI; Lee S; Park HK; Kim J; Oh S; Kim YA;
    Breast Cancer Res Treat; 2018 Jun; 169(2):311-322. PubMed ID: 29383628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2-Overexpressing Ductal Carcinoma
    O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer in young women and prognosis: How important are proliferation markers?
    Fredholm H; Magnusson K; Lindström LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
    Eur J Cancer; 2017 Oct; 84():278-289. PubMed ID: 28844016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials.
    Jensen MB; Nielsen TO; Knoop AS; Laenkholm AV; Balslev E; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):135-140. PubMed ID: 29168407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
    Ling DC; Sutera PA; Iarrobino NA; Diego EJ; Soran A; Johnson RR; Bhargava R; Champ CE; Beriwal S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):869-876. PubMed ID: 30885777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
    Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.